Source-grounded facts extracted from Cencora, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Samantha L. Hammock was appointed as Executive Vice President and Chief Human Resources Officer at Cencora, Inc..
“Ms. Battaglia will be succeeded by Samantha L. Hammock, who will join the Company as Executive Vice President and Chief Human Resources Officer effective July 13, 2026.”
Silvana Battaglia retired as Executive Vice President and Chief Human Resources Officer at Cencora, Inc..
“On June 15, 2026, Cencora, Inc. (the “Company”) announced that Silvana Battaglia will retire as Executive Vice President and Chief Human Resources Officer of the Company effective July 12, 2026.”
James F. Cleary departed as Executive Vice President and Chief Financial Officer at Cencora, Inc..
“Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously disclosed.”
Eva C. Boratto was appointed as Executive Vice President and Chief Financial Officer at Cencora, Inc..
“On May 27, 2026, Cencora, Inc. (the “Company”) announced that Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company (the “Appointment”), effective June 29, 2026 (the “Effective Date”).”
Cencora, Inc. reported the fiscal quarter ended March 31, 2026 results: revenue $78.4 billion, net income $1.6B, EPS $8.40. Guidance raised.
“Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $8.40 for the second quarter of fiscal 2026 compared to $3.68 in the prior year second quarter.”
Cencora, Inc. incurred senior notes of $3.0 billion aggregate principal amount with U.S. Bank Trust Company, National Association at 3.950%, 4.250%, 4.600%, 4.900%, 5.650% maturing February 13, 2029, November 15, 2030, February 13, 2033, February 13, 2036, February 13, 2056.
“On February 13, 2026, Cencora, Inc. (the “Company”) completed the sale of $3.0 billion aggregate principal amount of the Company’s Senior Notes”
Cencora, Inc. entered into Twenty-Second Supplemental Indenture with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee valued at $500,000,000 aggregate principal amount (effective 2026-02-13).
“The 2056 Notes were issued under and are governed by the Base Indenture, as supplemented and amended by a Twenty-Second Supplemental Indenture, dated as of February 13, 2026, by and between the Company and the Trustee (the “Twenty-Second Supplemental Indenture” and, together with the Base Indenture, the “2056 Note Indenture”).”
Cencora, Inc. entered into Twenty-First Supplemental Indenture with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee valued at $1,000,000,000 aggregate principal amount (effective 2026-02-13).
“The 2036 Notes were issued under and are governed by the Base Indenture, as supplemented and amended by a Twenty-First Supplemental Indenture, dated as of February 13, 2026, by and between the Company and the Trustee (the “Twenty-First Supplemental Indenture” and, together with the Base Indenture, the “2036 Note Indenture”).”
Cencora, Inc. entered into Twentieth Supplemental Indenture with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee valued at $500,000,000 aggregate principal amount (effective 2026-02-13).
“The 2033 Notes were issued under and are governed by the Base Indenture, as supplemented and amended by a Twentieth Supplemental Indenture, dated as of February 13, 2026, by and between the Company and the Trustee (the “Twentieth Supplemental Indenture” and, together with the Base Indenture, the “2033 Note Indenture”).”
Cencora, Inc. entered into Nineteenth Supplemental Indenture with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee valued at $500,000,000 aggregate principal amount (effective 2026-02-13).
“The 2030 Notes were issued under and are governed by the Base Indenture, as supplemented and amended by a Nineteenth Supplemental Indenture, dated as of February 13, 2026, by and between the Company and the Trustee (the “Nineteenth Supplemental Indenture” and, together with the Base Indenture, the “2030 Note Indenture”).”
Cencora, Inc. entered into Eighteenth Supplemental Indenture with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee valued at $500,000,000 aggregate principal amount (effective 2026-02-13).
“The 2029 Notes were issued under and are governed by an Indenture, dated as of November 19, 2009 (the “Base Indenture”), by and between the Company and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the “Trustee”), as supplemented and amended by an Eighteenth Supplemental Indenture, dated as of February 13, 2026, by and between the Company and the Trustee (the “Eighteenth Supplemental Indenture” and, together with the Base Indenture, the “2029 Note Indenture”).”
Cencora, Inc. entered into 364-Day Term Credit Agreement with Citibank, N.A. valued at $3.0 billion (effective 2026-01-12).
“On January 12, 2026, the Company entered into a Credit Agreement (the “364-Day Term Credit Agreement”), among the Company, the lenders party thereto and Citibank, N.A., as administrative agent, in connection with the Acquisition.”
Cencora, Inc. entered into Term Credit Agreement with JPMorgan Chase Bank, N.A. valued at $1.5 billion (effective 2026-01-12).
“On January 12, 2026, the Company entered into a Term Credit Agreement (the “Term Credit Agreement”), among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, in connection with the previously announced proposed acquisition (the “Acquisition”) of the majority of the outstanding equity interests that the Company does not currently own in OneOncology.”
Cencora, Inc. amended Incremental Facility and Amendment Agreement with JPMorgan Chase Bank, N.A. valued at $1.0 billion (effective 2026-01-12).
“On January 12, 2026, Cencora, Inc. (the “Company”) entered into an Incremental Facility and Amendment Agreement (the “Amendment”) to that certain Amended and Restated Credit Agreement (as amended by the Amendment, the “Revolving Credit Agreement”), dated as of June 4, 2025, among the Company, the borrowing subsidiaries party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent.”
Cencora, Inc. amended revolving credit of by $1.0 billion to $5.5 billion with JPMorgan Chase Bank, N.A., as administrative agent.
“The Amendment increased the aggregate amount of the commitments under the Revolving Credit Agreement by $1.0 billion to $5.5 billion.”
Cencora, Inc. incurred term loan of $3.0 billion with Citibank, N.A., as administrative agent at a rate equal to either a Term SOFR rate or a Daily Simple SOFR rate, plus an app maturing The 364-Day Term Loan matures 364 days from the date on which it is drawn.
“On January 12, 2026, the Company entered into a Credit Agreement (the "364-Day Term Credit Agreement"), among the Company, the lenders party thereto and Citibank, N.A., as administrative agent, in connection with the Acquisition. The 364-Day Term Credit Agreement provides for a senior unsecured term loan facility of $3.0 billion (the "364-Day Term Loan").”
Cencora, Inc. incurred term loan of $1.5 billion with JPMorgan Chase Bank, N.A., as administrative agent at a rate equal to either a Term SOFR rate or a Daily Simple SOFR rate, plus an app maturing Tranche One Loans mature two years from the date on which they are drawn. Tranche Two Loans mature three years from the date on which they are drawn.
“On January 12, 2026, the Company entered into a Term Credit Agreement (the "Term Credit Agreement"), among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, in connection with the previously announced proposed acquisition (the "Acquisition") of the majority of the outstanding equity interests that the Company does not currently own in OneOncology. The Term Credit Agreement provides for a senior unsecured term loan facility of $1.5 billion consisting of two tranches: (a) $500 million ("Tranche One Loans") and (b) $1.0 billion ("Tranche Two Loans" and together with Tranche One Loans, the "Term Loans").”
Cencora, Inc. amended credit facility of $1.5 billion with MUFG Bank, Ltd., as administrator.
“The Receivables Amendment added a new uncommitted purchaser, increased the size of the receivables securitization facility to $1.5 billion from $1.45 billion and amended the Company’s option to increase the commitments of the participating banks, subject to their approval, by an additional $500 million (the “Accordion Feature”), up from $250 million.”
Cencora, Inc. amended revolving credit of $4.5 billion with JPMorgan Chase Bank, N.A. at 69.5 basis points to 110 basis points over Term SOFR, Adjusted Term CORRA, Adjus maturing June 4, 2030.
““Revolving Credit Facility”). The Revolving Credit Facility was amended and restated to, among other things, (i) increase the aggregate amount of the commitments thereunder to $4.5 billion, (ii) extend the maturity date to June 4, 2030, and (iii) make certain changes to the covenants, representations and warranties and other provisions contained therein. Interest”
Ornella Barra resigned as Director at Cencora, Inc..
“Ornella Barra informed the Company of her intent to resign from the Board effective immediately”
Lori J. Ryerkerk was appointed as Director at Cencora, Inc..
“the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Lori J. Ryerkerk to serve on the Board (the “Appointment”), with such Appointment to be effective as of June 1, 2025”
Kathleen W. Hyle departed as Director at Cencora, Inc..
“On January 22, 2025, two members of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), Richard W. Gochnauer and Kathleen W. Hyle, each informed the Company of their intent to retire as directors at the upcoming Annual Meeting of Stockholders to be held on March 6, 2025 (the “Annual Meeting”).”
Richard W. Gochnauer departed as Director at Cencora, Inc..
“On January 22, 2025, two members of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), Richard W. Gochnauer and Kathleen W. Hyle, each informed the Company of their intent to retire as directors at the upcoming Annual Meeting of Stockholders to be held on March 6, 2025 (the “Annual Meeting”).”
Cencora, Inc. completed an acquisition involving Webster Equity Partners (seller) / Retina Midco, Inc. ("Retina Consultants of America" or "RCA") for $4.4 billion (closed 2025-01-02).
“in RCA of approximately 85%, with certain RCA physicians and members of the management team retaining a minority equity interest in RCA. The Company’s cash outlay at closing was $4.4 billion, which amount is subject to a customary post-closing purchase price adjustment. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 tm2432308d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press”
Frank Clyburn was appointed as Director at Cencora, Inc..
“On August 13, 2024, the Board of Directors (the "Board") of Cencora, Inc. (the "Company") appointed Frank Clyburn to serve on the Board (the "Appointment"), with such Appointment to be effective as of October 1, 2024 (the "Effective Date").”
Cencora, Inc. disclosed a cybersecurity incident: data exfiltration from information systems, including personally identifiable information and protected health information. Impact: no material impact on operations or financial condition. Company determined it not material. Discovered 2024-02-21.
“The incident has not had a material impact on the Company’s operations, and its information systems have continued to be fully operational. The Company does not believe the incident is reasonably likely to materially impact the Company’s financial condition or results of operations.”
Gina K. Clark departed as Executive Vice President and Chief Communications & Administrative Officer at Cencora, Inc..
“On April 30, 2024, Gina K. Clark, Executive Vice President and Chief Communications & Administrative Officer of Cencora, Inc. (the “Company”), informed the Company that she intends to retire from her position, effective September 30, 2024.”
Cencora, Inc. amended Omnibus Amendment with MUFG Bank, Ltd., as administrator, and the purchaser agents and purchasers party thereto (effective 2024-04-17).
“On April 17, 2024, Cencora, Inc. (the “ Company ”) and certain of its subsidiaries entered into an Omnibus Amendment (the “ Omnibus Amendment ”) with MUFG Bank, Ltd., as administrator, and the purchaser agents and purchasers party thereto”
Cencora, Inc.: Amended and restated certificate of incorporation to permit officer exculpation and effect miscellaneous clarifications (effective 2024-03-14).
“The Amended and Restated Certificate of Incorporation became effective upon its filing with the Secretary of State of the State of Delaware on March 14, 2024.”
Cencora, Inc. shareholders approved Item 5 – Approval of Miscellaneous Amendments to the Company’s Certificate of Incorporation at the 2024-03-12 meeting.
“The Company’s shareholders approved this item.”
Cencora, Inc. shareholders approved Item 4 – Approval of an Amendment of the Company’s Certificate of Incorporation to Provide for the Exculpation of Officers as Permitted by Delaware Law at the 2024-03-12 meeting.
“The Company’s shareholders approved this item.”
Cencora, Inc. shareholders approved Item 3 - Ratification of Appointment of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2024 at the 2024-03-12 meeting.
“The Company’s shareholders approved this item.”
Cencora, Inc. shareholders approved Item 2 - Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2024-03-12 meeting.
“The Company’s shareholders approved this item.”
Cencora, Inc. shareholders approved Item 1 - Election of Directors at the 2024-03-12 meeting.
“Each of the individuals listed below was elected by the Company’s shareholders to serve as a director until the 2025 Annual Meeting of Shareholders and until his or her successor is duly elected and qualified.”
Steven H. Collis changed role as Executive Chairman at Cencora, Inc..
“For a period of one year from the Effective Date, Mr. Collis will serve as Executive Chairman of the Board (the “Executive Chairman Period”).”
Robert P. Mauch was appointed as Chief Executive Officer at Cencora, Inc..
“On March 12, 2024, the Company and Mr. Mauch entered into an amended and restated employment agreement (the “Mauch Employment Agreement”), effective as of the Effective Date.”
Robert P. Mauch was appointed as President and Chief Executive Officer at Cencora, Inc..
“the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) unanimously selected Robert P. Mauch to succeed Steven H. Collis as the Company’s President and Chief Executive Officer (“CEO”), effective October 1, 2024 (the “Effective Date”), at which time he will also join the Board.”
Steven H. Collis changed role as Executive Chairman at Cencora, Inc..
“Mr. Collis, who has served as CEO since July 2011, will retire from the role of CEO and become Executive Chairman of the Board as of the Effective Date, to serve for a period of one year.”
Cencora, Inc. disclosed a cybersecurity incident: data from its information systems had been exfiltrated, some of which may contain personal information. Impact: the incident has not had a material impact on the Company’s operations, and its information systems continue to be operational. Materiality is still being assessed. Discovered 2024-02-21.
“On February 21, 2024, Cencora, Inc. (the “Company”), learned that data from its information systems had been exfiltrated, some of which may contain personal information.”
Cencora, Inc. entered into Share Repurchase Agreement with Walgreens Boots Alliance Holdings LLC valued at approximately $50 million (effective 2024-02-07).
“On February 7, 2024, Cencora, Inc. (the “Company”) entered into a share repurchase agreement (the “Share Repurchase Agreement”) with Walgreens Boots Alliance Holdings LLC (the “Selling Stockholder”), pursuant to which the Company agreed to repurchase 212,395 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) directly from the Selling Stockholder (the “Repurchase”).”
Cencora, Inc. reported the fiscal quarter ended December 31, 2023 results: revenue $72.3 billion, net income $602M, EPS $2.98. Guidance raised.
“CENCORA REPORTS FISCAL 2024 FIRST QUARTER RESULTS Revenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28 Adjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024 CONSHOHOCKEN, PA, January 31, 2024 - Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 21.0 percent to $3.28 in the fiscal first quarter from $2.71 in the prior year first quarter. Cencora is updating its outlook for fiscal year 2024. The Company does not provide forward-lookin”
Henry W. McGee retired as Director at Cencora, Inc..
“On January 12, 2024, Henry W. McGee, a member of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), informed the Board of his intent to retire and not stand for re-election as a director when his term expires at the Company's 2024 Annual Meeting of Stockholders to be held on March 12, 2024”
Cencora, Inc.: Amended and restated bylaws to clarify standard for election of directors, specifying majority vote except in contested elections where plurality vote applies (effective 2023-12-26).
“On December 26, 2023 the Board of Directors of Cencora, Inc. (the “Company”) approved an amendment and restatement of the Company’s bylaws (as amended and restated, the “Amended and Restated Bylaws”), effective immediately, to provide clarifying edits with respect to the standard for the election of directors set forth in Section 2.09(b) of the Amended and Restated Bylaws.”
Cencora, Inc. entered into Share Repurchase Agreement with Walgreens Boots Alliance Holdings LLC valued at approximately $250 million (effective 2023-11-09).
“On November 9, 2023, Cencora, Inc. (the “Company”) entered into a share repurchase agreement (the “Share Repurchase Agreement”) with Walgreens Boots Alliance Holdings LLC (the “Selling Stockholder”), pursuant to which the Company agreed to repurchase 1,279,590 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) directly from the Selling Stockholder (the “Repurchase”).”
Cencora, Inc. reported the fiscal year 2023 fourth quarter ended September 30, 2023 results: revenue $68.9 billion, EPS $1.72.
“as shall be expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- CENCORA REPORTS FISCAL 2023 FOURTH QUARTER AND YEAR END RESULTS Revenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86 Revenue of $262.2 Billion for Fiscal”
Cencora, Inc. reported the fiscal year ended September 30, 2023 results: revenue $262.2 Billion, EPS $8.53.
“CENCORA REPORTS FISCAL 2023 FOURTH QUARTER AND YEAR END RESULTS Revenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86 Revenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase Fiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99”
Cencora, Inc. amended Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent (effective 2023-10-06).
“On October 6, 2023, Cencora, Inc. (the “Company”) and its subsidiaries BP Pharmaceuticals Laboratories Unlimited Company, Centaur Services Limited and Innomar Strategies Inc. entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) to amend and restate the Amended and Restated Credit Agreement, dated as of October 27, 2022, among the Company, the borrowing subsidiaries party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent”
Cencora, Inc.: Company amended and restated its bylaws effective August 30, 2023 to reflect the name change (effective 2023-08-30).
“The Company also amended and restated its bylaws effective August 30, 2023 to reflect the Name Change.”
Cencora, Inc.: Company amended and restated its certificate of incorporation to change its name from AmerisourceBergen Corporation to Cencora, Inc (effective 2023-08-30).
“On August 30, 2023, AmerisourceBergen Corporation (the “Company”) changed its name to Cencora, Inc. pursuant to an amended and restated certificate of incorporation filed with the Secretary of State of the State of Delaware (the “Name Change”).”
Lauren Tyler was elected as Director at Cencora, Inc..
“On August 9, 2023, the Board of Directors (the “Board”) of AmerisourceBergen Corporation (the “Company”) elected Werner Baumann, 60, and Lauren Tyler, 61, to serve on the Board, effective October 1, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.